Asia Fresh News

Asia Fresh Stories

Archive for June 7th, 2016

Nexusguard Scoops Prestigious Customer Service Award for Fourth Year in a Row

leave a comment »

HONG KONG /PRNewswire/ — Nexusguard, the global leader in DDoS mitigation, today announced that it has been awarded Asia Pacific Customer Service Consortium’s “Customer Service Quality Standard (CSQS) certification” for the fourth consecutive year. The CSQS is the most recognized global award for CRM, Customer Service, and Contact Center and Support Services — in serving customers to improve business performance, to align the service approach internally and to improve inter departmental and companywide integration. Nexusguard is the single tech firm winning the prestigious accolade.

Nexusguard is dedicated to putting customer service excellence first. Relationship Managers (RM) and Technical Account Managers (TAM) work together to provide professional support and solutions, bringing customer peace of mind to their business. Adrian Luwa, Director of Operations at Nexusguard, emphasized: “Our professional team continues to uphold our commitment – customer-oriented and continues to strive for innovation in order to offer premium service to our customers who are under a multitude of threats, including distributed denial of service (DDoS) attacks, to ensure uninterrupted internet service.”

The CSQS award scores nominees in three key service areas: Operation Service Center, Proactive Service Center, and Strategic Business Unit. CSQS is granted if a company excels in all three, surpassing industry benchmarks. The panel scores how well companies have adopted Customer Service Knowledge Management (CSKM) to empower frontline staff to deliver a superior customer experience.

As the global cybersecurity leader, it is a solid recognition and affirmation for exceptionally well-qualified service. Nexusguard strives to improve customer experience delivery beyond providing service availability. Nexusguard provides highly customized services, backed by actionable insights, to meet or exceed  the unique requirements of every customer.

About Nexusguard

Founded in 2008, Nexusguard is the global leader in fighting malicious internet attacks. Nexusguard protects clients against a multitude of threats, including distributed denial of service (DDoS) attacks, to ensure uninterrupted internet service. Nexusguard provides comprehensive, highly customized solutions for customers of all sizes, across a range of industries, and also enables turnkey anti-DDoS solutions for service providers. Nexusguard delivers on its promise to maximize peace of mind by minimizing threats and improving uptime. Headquartered in San Francisco, Nexusguard’s network of security experts extends globally. Visitwww.nexusguard.com for more information.

Press Contact
Benjamin Yip
Head of Marketing, Asia Pacific
D: +852 3526 0626
benjamin.yip@nexusguard.com

Crystal Ngan
Senior Marketing Communications Executive, Asia Pacific
D: +852 3910 0565
crystal.ngan@nexusguard.com

Source: Nexusguard

Written by asiafreshnews

June 7, 2016 at 3:52 pm

Posted in Uncategorized

DHL Global Forwarding Announces Appointment of New CEO in India

leave a comment »

MUMBAI, India /PRNewswire/ — DHL Global Forwarding, the leading international provider of air, sea, and road freight services, announced the appointment of George Lawson as Chief Executive Officer and Country Manager forIndia, effective June 1, 2016. Relocated from Bonn, Germany, George is now based in Mumbai. In his new role as a member of the Asia Pacific Management Board, George reports to Kelvin Leung, CEO, DHL Global Forwarding Asia Pacific.

George Lawson, Chief Executive Officer and Country Manager, DHL Global Forwarding India
George Lawson, Chief Executive Officer and Country Manager, DHL Global Forwarding India

 

“With the Indian economy expected to grow at 7.5 per cent in FY 2016-17[1], India remains a key strategic region for DHL and we see tremendous opportunities in the country,” said Kelvin Leung, CEO, DHL Global Forwarding Asia Pacific. “George has successfully executed global strategies to drive growth and has a deep understanding of our business through the last two decades he spent with DHL. His experience will be beneficial in bringing our business growth to new heights in India.”

George joined DHL in 1992 and has worked in a number of leadership positions across different disciplines including Sales, Operations, Marketing and General Management in Asia and Europe, including a stint as Chief Operating Officer, Singapore. Most recently, George was the Senior Vice President Global Head of Marketing and is the key architect of DHL Global Forwarding’s Certified International Forwarder program that engages employees and develops their expertise to drive outstanding customer experience and financial results.

“With India gathering momentum to hold its ranking as the world’s fastest growing large economy in the first quarter this year[2], it’s an exciting time to be here,” said George Lawson. “It’s a privilege to lead our India team that has consistently delivered high quality solutions for our customers.”

In India, DHL Global Forwarding provides sector-focused solutions for Technology, Engineering & Manufacturing, Fashion, Life Sciences & Healthcare, Automotive, Energy and Chemicals. The company also supports the growth of SME segment in India by offering access to the worldwide markets through the extensive DHL global network. DHL Global Forwarding has also made significant investments in its Free Trade Zone facilities in Mumbai andChennai.

With a vast array of product portfolio including Air and Ocean Freight, Customs Brokerage, Customs Consultancy, Industrial Projects and Oil & Gas, supported by a strong global network, DHL Global Forwarding will continue to offer high quality one-stop solutions for its customers.

– End –

DHL – The logistics company for the world

DHL is the leading global brand in the logistics industry. Our DHL family of divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With about 340,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, energy, automotive and retail, a proven commitment to corporate responsibility and an unrivalled presence in developing markets, DHL is decisively positioned as “The logistics company for the world”.

DHL is part of Deutsche Post DHL Group. The Group generated revenues of more than 59 billion euros in 2015.

Photo – http://photos.prnasia.com/prnh/20160606/8521603580
Logo – http://photos.prnasia.com/prnh/20150811/8521505246LOGO

Source: DHL

Written by asiafreshnews

June 7, 2016 at 3:47 pm

Posted in Uncategorized

Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial

leave a comment »

DARMSTADT, Germany /PRNewswire/ —

Not intended for UK- or US-based media

  • BEACON CRC trial will assess efficacy of combination regime Erbitux® (cetuximab), binimetinib and encorafenib in BRAF-mutant metastatic colorectal cancer (mCRC)

Merck, a leading science and technology company, jointly announced with Array BioPharma Inc. and Pierre Fabre, the initiation of a prospective, randomized, global Phase III clinical trial of BRAF-mutant metastatic colorectal cancer (mCRC), investigating a new combination of Erbitux® (cetuximab), a standard-of-care treatment for RAS wild-type mCRC, plus encorafenib with or without binimetinib. The BEACON CRC (Binimetinib, Encorafenib AndCetuximab Combined to treat BRAF-mutant Colorectal Cancer) trial will assess the efficacy and safety of these two novel combinations in patients with BRAF-mutant tumors, compared with investigator’s choice of Erbitux plus irinotecan or Erbitux plus FOLFIRI.

(Logo: http://photos.prnewswire.com/prnh/20151207/293543LOGO )
(Logo: http://photos.prnewswire.com/prnh/20151019/278051LOGO )

“This trial looking specifically at BRAF-mutated tumors exemplifies our ongoing commitment to exploring Erbitux as an ‘anchor’ treatment in combination with other therapies,” said Luciano Rossetti, Executive Vice President, Head of Global Research & Development at the biopharma business of Merck. “There is a clear need for effective treatment regimens for the BRAF-mutant mCRC population; the results of the BEACON CRC trial will hopefully provide us with the prospective information we need to take us one step closer to achieving that goal.”

Colorectal cancer (CRC) is one of the most challenging types of cancers, with an estimated 10 percent of CRCs associated with an oncogenic mutation in the BRAF gene.[1] Studies have observed that patients with BRAF-mutant mCRC have shorter progression-free survival and overall survival.[2] Additional treatment regimens are needed that can effectively combat these cancers.

“Historical studies suggest that BRAF-mutant colorectal cancer patients who have progressed after first-line systemic treatment have an estimated median overall survival of less than 6 months,” said Dr. Josep Tabernero, MD, PhD, Head of Medical Oncology and the Institute of Oncology at Vall d’Hebron University Hospital. “The BEACON CRC trial will explore innovative combinations which have the potential to offer new treatment options to these patients, who currently have few good choices remaining.”

“We are pleased to join Merck on this innovative trial for patients with BRAF-mutant metastatic colorectal cancer,” said Victor Sandor, MD, Chief Medical Officer of Array BioPharma. “The encouraging results from our Phase II study suggest that concurrent inhibition of EGFR and enzymes in the MAPK signaling pathway has the potential to improve outcomes for this patient population, and we look forward to the results of this further investigation.”

Approximately 650 patients are expected to be enrolled by 2018 and, after a lead-in period to assess the safety and tolerability of Erbitux plus encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor), will be randomized to receive one of the two novel combinations, or investigator’s choice. The primary endpoint of the trial is overall survival. Key secondary endpoints include progression-free survival, objective response rate, duration of response, safety and tolerability. The trial will also assess health-related quality of life.

References

  1. Barras D. Biomark Cancer. 2015;7(Suppl 1):9-12.
  2. Saridaki Z. PLoS One. 2013 Dec 18;8(12):e84604. doi: 10.1371.
  3. Vaughn CP et al. Genes Chromosomes Cancer 2011;50(5):307−12.
  4. Bokemeyer C et al. J Clin Oncol 2014;32:(Suppl 4): abstr 3505.
  5. Van Cutsem E et al. J Clin Oncol 2015;33(7):692-700.
  6. Stintzing S et al. Ann Oncol 2014;25(Suppl 4) abstr LBA11.
  7. Lenz H et al. Ann Oncol 2014;25(Suppl 4) abstr 501O.
  8. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr , accessed June 2015.

About BRAF Mutations

BRAF is an important actor in the epidermal growth factor receptor(EGFR)-mediated mitogen-activated protein kinase (MAPK) pathway, which strongly impacts cell growth and proliferation, as well as cell migration, cell death and cell survival.[1]

About mCRC

Approximately half of patients with mCRC have RAS wild-type tumors and half have RAS mutant tumors.[3]Results from studies assessing RAS mutation status in patients with mCRC have shown that anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies, such as Erbitux® (cetuximab), can improve outcomes in patients with RAS wild-type mCRC.[4][7] CRC is the third most common cancer worldwide, with an estimated incidence of more than 1.36 million new cases annually.[7] An estimated 694,000 deaths from CRC occur worldwide every year, accounting for 8.5% of all cancer deaths and making it the fourth most common cause of death from cancer.[8] Almost 55% of CRC cases are diagnosed in developed regions of the world, and incidence and mortality rates are substantially higher in men than in women.[8]

About Erbitux (cetuximab)

Erbitux® is a highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth.

The most commonly reported side effect with Erbitux is an acne-like skin rash that seems to be correlated with a good response to therapy. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.

Erbitux has already obtained market authorization in over 90 countries world-wide for the treatment of colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Merck licensed the right to market Erbitux outside the US and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998. Merck has an ongoing commitment to the advancement of oncology treatment and is currently investigating novel therapies in highly targeted areas.

About Binimetinib & Encorafenib

MEK and RAF are key protein kinases in the RAS-RAF-MEK-ERK-pathway. Research has shown this pathway regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Inappropriate activation of proteins in this pathway has been shown to occur in many cancers, such as non-small cell lung cancer, melanoma, colorectal and thyroid cancer. Binimetinib is a small molecule MEK inhibitor and encorafenib is a small molecule RAF inhibitor, each of which target key enzymes in this pathway. There are three active Phase III trials which include these products: NRAS-mutant melanoma (NEMO, with binimetinib), BRAF-mutant melanoma (COLUMBUS, with binimetinib and encorafenib) and BRAF-mutant colorectal cancer (BEACON CRC, with binimetinib and encorafenib).

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

For further details and press materials about Merck products please visit www.merckgroup.com/media-center-oncology .

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Contact: Gangolf Schrimpf +49-6151-72-9591

Frankfurter Strasse 250
64293 Darmstadt, Germany
Hotline +49-6151-72-5000
merckgroup.com

Head Media Relations -62445
Spokesperson: -9591 / -7144 / -6328
Fax +49 6151 72 3138
media.relations@merckgroup.com

Source: Merck

Written by asiafreshnews

June 7, 2016 at 3:41 pm

Posted in Uncategorized

ContourGlobal Commences Tender Offer for any and all of its 7.125% Senior Secured Notes Due 2019

leave a comment »

LUXEMBOURG /PRNewswire/ — ContourGlobal Power Holdings S.A. (the “Issuer”) today announced that it has commenced a cash tender offer (the “Tender Offer”) for any and all of its outstanding 7.125% senior secured notes due 2019 (the “Notes”).

The Tender Offer is scheduled to expire at 5:00 p.m., New York City time, June 14, 2016, unless extended or earlier terminated (such time, as may be extended, the “Expiration Time”). Holders who validly tender the Notes prior to the Expiration Time will be eligible to receive $1,037.51 for each $1,000 principal amount of Notes, plus any accrued and unpaid interest up to, but excluding, the settlement date.

Tendered Notes may be withdrawn at any time on or prior to the Expiration Time. Completion of the Tender Offer is subject to certain market and other conditions, including the consummation of one or more debt financing transactions. Settlement of the Tender Offer will occur promptly after the Expiration Time, unless earlier terminated, which is expected to be June 17, 2016.

The Issuer intends to deliver a notice of redemption in order to redeem any Notes outstanding following the consummation of the Tender Offer.

The complete terms and conditions of the Tender Offer are described in the Offer to Purchase, dated June 6, 2016, and the related Notice of Guaranteed Delivery, copies of which may be obtained from Lucid Issuer Services Limited, the tender and information agent for the Tender Offer, at http://library.lucid-is.com/contourglobal or Attn: Paul Kamminga, +44 (0)20 7704 0880, contourglobal@lucid-is.com.

The Issuer has retained Goldman Sachs International to serve as the dealer manager for the Tender Offer. Questions regarding the tender offer may be directed to Goldman Sachs International at Attn: Liability Management Group, +44 (0)20 7774 9862, +1 (800) 828-3182 (toll-free), +1 (212) 902-6941 (collect).

None of the Issuer, the dealer manager, the trustee for the Notes or the tender and information agent make any recommendations as to whether holders should tender their Notes pursuant to the Tender Offer, and no one has been authorized by any of them to make such recommendations. Holders must make their own decisions as to whether to tender their Notes, and, if so, the principal amount of Notes to tender.

This press release is for informational purposes only and is not an offer to purchase or a solicitation of an offer to purchase or sell the Notes or any other securities, nor shall there be any purchase of the Notes in any state or jurisdiction in which such offer, solicitation or purchase would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The tender offer is being made solely pursuant to the Offer to Purchase, dated June 6, 2016, and the related Notice of Guaranteed Delivery, which set forth the complete terms of the tender offer. Any offers of concurrently offered securities will be made only by means of a private offering memorandum.

About ContourGlobal
The Issuer is a finance subsidiary wholly-owned by ContourGlobal L.P., a Cayman Islands exempted limited partnership (together with its consolidated subsidiaries, “ContourGlobal”). ContourGlobal is a premier developer and operator of wholesale electric power generation businesses in 20 countries worldwide.

Forward Looking Statements
This press release contains forward-looking statements. Actual results may differ materially from those reflected in the forward-looking statements. The Issuer undertakes no obligation to release publicly the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof, including, without limitation, changes in ContourGlobal’s business or to reflect the occurrence of unanticipated events.

Source: ContourGlobal

Written by asiafreshnews

June 7, 2016 at 3:25 pm

Posted in Uncategorized

Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA

leave a comment »

BAGSVAERD, Denmark /PRNewswire/ —

This material is intended for global medical media only.

For journalistic assessment and preparation before publication.

Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA, from 10-14 June.

Following are key highlights that will be presented at the meeting:

12 June, 8.30 am CDT, oral presentation

  • Phase 3a results from the SUSTAIN 2 clinical study comparing the efficacy and safety of semaglutide with sitagliptin in people with type 2 diabetes (#185-OR)

12 June, 9.00 am CDT, oral presentation

  • Phase 3a results from the SUSTAIN 3 clinical study comparing the efficacy and safety of semaglutide with exenatide extended release (ER) in people with type 2 diabetes (#187-OR)

12 June, 12.00 pm CDT, poster presentation

  • Phase 3b results from the SWITCH clinical studies comparing the hypoglycaemia occurrence in people with type 1 diabetes on basal-bolus insulin and type 2 diabetes on basal insulin treated with Tresiba® (insulin degludec injection 100 Units/mL) vs insulin glargine U-100 in a blinded setting (#87-LB and #90-LB)

12 June, 3.00 pm CDT and 13 June, 8.45 am CDT, oral presentations

  • Phase 3a results from the onset clinical trials evaluating the efficacy of faster-acting insulin aspart vs insulin aspart in people with type 1 and type 2 diabetes (#293-OR, #240-OR)

12 June, 2.45 pm CDT, oral presentation

  • Results from DUAL V on IDegLira vs insulin glargine U-100 comparing safety and efficacy in patients with uncontrolled type 2 diabetes (#239-OR)

13 June, 2.15 pm CDT, oral presentation

  • Results from LEADER, a cardiovascular outcomes trial which investigated the cardiovascular safety of Victoza® (liraglutide) injection in people with type 2 diabetes at high risk of major adverse cardiovascular events

11 June, 12.30 pm CDT, moderated poster discussion; 13 June, 12.00 pm CDT, poster presentation

  • Data from the 2nd Diabetes Attitudes, Wishes and Needs (DAWN2) Study relating to ‘Concerns about Hypoglycemia’ (#667-P)

ADA 2016 will be a landmark congress for Novo Nordisk. This year, we have an unprecedented amount of key clinical data on our new insulins and GLP-1, and we look forward to sharing it all with the medical and scientific community,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “The presented research demonstrates advances in several areas of diabetes, underscoring our focus on developing innovative treatments with the potential to improve the lives of people with diabetes.”

The above abstracts are a sampling of the data that will be presented or published by Novo Nordisk. For a complete list of abstracts please click here: www.abstractsonline.com/pp8/#!/4008 .

This press release contains forward-looking statements about investigational products currently in development by Novo Nordisk. As is expected, there is significant risk with drug development and there is no guarantee that future studies will reflect similar results as presented at ADA. For further information about the Novo Nordisk drug pipeline, visit www.novonordisk.us.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information
Media:
Katrine Sperling
+45-4442-6718
krsp@novonordisk.com

Åsa Josefsson
+45-3079-7708
aajf@novonordisk.com

Michael Bachner
+1-609-664-7308
mzyb@novonordisk.com

Chris Clark
+1-609-619-1831
cpcr@novonordisk.com

Investors:
Peter Hugreffe Ankersen
+45-3075-9085
phak@novonordisk.com

Melanie Raouzeos
+45-3075-3479
mrz@novonordisk.com

Kasper Veje (US)
+1-609-235-8567
kpvj@novonordisk.com

Source: Novo Nordisk

Written by asiafreshnews

June 7, 2016 at 2:41 pm

Posted in Uncategorized

Cambium Networks Announces cnPilot™ E500, High-Capacity Outdoor WiFi Access Point Providing Network Connectivity in High-Density Areas Under Demanding Conditions

leave a comment »

— The E500 offers high-powered processing in any outdoor environment with the flexibility of end-to-end cloud-based network management –

ROLLING MEADOWS, Illinois /PRNewswire/ — Cambium Networks™, a leading global provider of wireless broadband solutions, today debuted the cnPilot E500, a high-capacity controller managed outdoor WiFi access point that provides connectivity under demanding conditions. The IP67 grade 802.11ac dual-band AP supporting 16 SSIDs and up to 256 users is perfect for Enterprises, Service Providers, and Industrial users looking for an affordable, yet reliable high-performance WLAN solution.

Logo – http://photos.prnewswire.com/prn/20140613/117974

The cnPilot E500 delivers features typically found in access points at twice the price. Packing a high transmit power of 29 dBm, the ability to daisy-chain power via a PoE out port to power a security camera or a wireless backhaul link node, an LTE co-existence filter to filter out nearby small cell LTE interference, the E500 can support a large number of users in difficult outdoor conditions perfect for any location where a high-performance outdoor 802.11ac WLAN Access Point is needed. The E500 is easily managed through cnMaestro™, the Cambium Networks cloud-based or on-premises based WiFi controller.

Key features of E500 include:

  • Designed for high-capacity situations, supporting up to 256 active users and 16 SSIDs
  • IP67 rated with pressure vent – made to withstand demanding outdoor environments, resistant to wind, sand and rain, and prevent internal damage from moisture accumulation
  • Mesh backhauling capability for convenient outdoor deployments
  • Best radio for the price point, offering reliable, high-capacity solution at a significantly lower cost than comparable competitors
  • Easy to deploy and integrate, supported by cnMaestro’s controller capabilities

“The E500 has proven that it can support the extensive network demands of our public WiFi and public safety equipment,” said Brian Magnuson, President of Cascade Networks, Washington, USA. “The radio is positioned in an area subject to extreme outdoor environmental and RF conditions and the network has performed reliably no matter the situation. The product was extremely easy to deploy and has brought much-needed connectivity and processing power to an otherwise underserved area.”

“High capacity Outdoor deployments need the power of backhaul flexibility when wired networks are not available, and cnPilot E500 provides two options,” said Vibhu Vivek, Senior Vice President of Products for Cambium Networks. “It can be configured to be backhauled by Cambium’s proven ePMP, PMP or PTP solutions for longer distances, or deployed in a mesh configuration where it can form wireless links with any of our indoor and outdoor WiFi access points.”

Cambium Networks will present a webinar on the E500 and other WiFi solutions on June 8 and 9. Click here to register. The cnPilot E500 is available now through Cambium Networks distributors.

For more information on Cambium’s cnPilot line of Wi-Fi solution products, please visit our user community athttp://community.cambiumnetworks.com/t5/cnPilot/ct-p/WiFi or http://www.cambiumnetworks.com/products/wifi/.

About Cambium Networks:

Cambium Networks is a leading global provider of wireless broadband solutions that connect the unconnected. Through its extensive portfolio of reliable, scalable and secure wireless broadband point-to-point (PTP) and point-to-multipoint (PMP) platforms, Cambium Networks makes it possible for all service providers; enterprises; governmental and military agencies; oil, gas and utility companies; Internet service providers; and public safety networks to build powerful, easily sustainable communications networks. The company currently has over five million of its access and backhaul radios deployed in thousands of demanding networks in more than 150 countries. Headquartered outside Chicago and with R&D centers in the U.S., Ashburton, U.K. and Bangalore, India, Cambium Networks sells through a range of trusted global distributors. For more information, visit:www.cambiumnetworks.com and www.connectingtheunconnected.org.

Contact

Golin for Cambium Networks – Cyrus Hedayati
+1 415 318 4377
chedayati@golin.com

Source: Cambium Networks

Written by asiafreshnews

June 7, 2016 at 2:33 pm

Posted in Uncategorized

ContourGlobal Announces Private Offering of Senior Secured Notes

leave a comment »

LUXEMBOURG /PRNewswire/ — ContourGlobal Power Holdings S.A. (the “Issuer”) today announced its intention to offer €550 million aggregate principal amount of senior secured notes due 2021 (the “Notes”) in a private offering to eligible purchasers.

The Issuer intends to use the net proceeds from the offering to refinance outstanding indebtedness, including its senior secured notes due 2019, pay related fees and expenses and for general corporate purposes.

The Notes are being offered in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), only to qualified institutional buyers in reliance on Rule 144A under the Securities Act and, outside the United States, to non-U.S. investors pursuant to Regulation S under the Securities Act. The Notes will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements or a transaction not subject to the registration requirements of the Securities Act or any state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About ContourGlobal
The Issuer is a finance subsidiary wholly-owned by ContourGlobal L.P., a Cayman Islands exempted limited partnership (together with its consolidated subsidiaries, “ContourGlobal”). ContourGlobal is a premier developer and operator of wholesale electric power generation businesses in 20 countries worldwide.

Forward Looking Statements
This press release contains forward-looking statements. Actual results may differ materially from those reflected in the forward-looking statements. The Issuer undertakes no obligation to release publicly the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof, including, without limitation, changes in ContourGlobal’s business or to reflect the occurrence of unanticipated events.

Source: ContourGlobal

Written by asiafreshnews

June 7, 2016 at 2:24 pm

Posted in Uncategorized

SIRveNIB, a Major Primary Liver Cancer Study in the Asia-Pacific Region, Completes Enrolment

leave a comment »

SINGAPORE /PRNewswire/ —

Results of Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC) Randomised Controlled Study Comparing Sorafenib and SIR-Spheres® Y-90 resin microspheres in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) Expected in 2017

The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore, Singapore Clinical Research Institute (SCRI) and Sirtex Medical Limited announced that the AHCC protocol 06 SIRveNIB randomised controlled study of SIR-Spheres Y-90 resin microspheres versus sorafenib in the treatment of unresectable primary liver cancer (hepatocellular carcinoma or HCC) has completed its target enrolment of at least 360 patients.[1]

SIRveNIB was designed to compare the efficacy and safety of selective internal radiation therapy (SIRT) with yttrium-90 [Y-90] resin microspheres (SIR-Spheres® Sirtex Medical Limited, North Sydney, Australia) versus sorafenib (Nexavar®, Bayer HealthCare Pharmaceuticals, Berlin, Germany), a systemic treatment that is the current standard of care in advanced hepatocellular carcinoma. The patients in SIRveNIB were ineligible for potentially curative therapies, such as surgical resection, ablation or liver transplantation.

Professor Pierce Chow, Principal Investigator of the SIRveNIB study, and Senior Consultant Surgeon at the National Cancer Centre Singapore and the Singapore General Hospital, explained that, “The search for more effective and better tolerated treatments of HCC is important, as so few proven treatment options currently exist. Beyond the primary endpoint of overall survival in SIRveNIB, we are also looking at a number of important secondary endpoints including a comparison of the side effects and patient quality of life with these two very different approaches to treating unresectable HCC. SIRveNIB is the largest Asia-Pacific study to directly compare SIRT and sorafenib, and indeed is the largest randomised study conducted on sorafenib in the region.”

“Completion of patient enrolment in the investigator-led SIRveNIB study represents a milestone in Asian liver cancer research, and underscores the strong private-public partnership that exists between Sirtex Medical Limited, the National Cancer Centre Singapore and Singapore Clinical Research Institute,” said Associate Professor Teoh Yee Leong, CEO Singapore Clinical Research Institute.

SIRveNIB patients were treated at 27 centres across 10 Asia-Pacific countries including New Zealand. The results of SIRveNIB are expected to become available in the first half of 2017.

Sorafenib was established as the standard treatment for patients with advanced HCC following the results of two pivotal randomized controlled trials which demonstrated an increased overall survival compared to placebo.[2],[3] However, 80% of patients receiving sorafenib also experienced treatment-related adverse events. SIRT with SIR-Spheres Y-90 resin microspheres is an approved treatment for inoperable liver tumours. It is a minimally-invasive treatment that delivers high-energy beta radiation directly to the tumours. SIRT is administered to patients by interventional radiologists, who infuse millions of radioactive microspheres (whose diameters are around 32.5 microns, or about one-third the diameter of a human hair) via a catheter into the liver arteries that supply blood to the tumours. The microspheres use the tumours’ own blood supply to deliver a dose of short-range radiation that is up to 40 times higher than conventional radiotherapy, while sparing healthy tissue. Interest in a randomized controlled study of SIRT using Y-90 resin microspheres in this patient population was based on a substantial number of open-label single-centre studies as well as a large multi-centre analysis of the long-term outcomes following SIR-SpheresY-90 resin microspheres in patients with inoperable HCC.[4]

Current Availability of SIR-Spheres Y-90 resin microspheres

SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumours in Australia, the European Union (CE Mark), Argentina (ANMAT), Brazil, and several countries in Asia, such as Turkey, India andSingapore. The product is also supplied for this use in countries and regions such as Hong Kong, Israel, Malaysia,New Zealand, Taiwan and Thailand. SIR-Spheres Y-90 resin microspheres also have a full Pre-Market Approval (PMA) by the FDA and are indicated in the United States for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine.

About Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer – cancer that starts in the liver – which is the sixth most-common cancer in the world and the second most-common cause of cancer-related death.[5] It affects mainly patients with cirrhosis from any cause, including viral hepatitis and alcohol abuse. HCC occurs with greatest frequency in regions where hepatitis is most often diagnosed, such as in the Asia Pacific region andSouthern Europe. When diagnosed in its early stages, HCC can be treated by surgical resection, ablation or liver transplantation with expectation of improved long-term survival. However, these options are not available to the great majority of patients. For patients with unresectable HCC, the outlook is bleak, with survival ranging from a few months to about two years depending largely on the extent of their tumours and state of their liver at the time of diagnosis.[6] No new HCC treatment option has been tested successfully in large studies for almost a decade.

About the SIRveNIB Study Sponsors

SIRveNIB is an investigator-initiated study sponsored by Singapore General Hospital in collaboration with National Medical Research Council, Singapore, National Cancer Centre Singapore, and the Singapore Clinical Research Institute and Sirtex Medical Limited.

For further information, please visit:

Singapore General Hospital http://www.sgh.com.sg
National Medical Research Council, Singapore http://www.nmrc.gov.sg
National Cancer Centre Singapore http://www.nccs.com.sg
Singapore Clinical Research Institute http://www.scri.edu.sg
Sirtex Medical Limited  http://www.sirtex.com

References:

  1. Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB): http://clinicaltrials.gov/ct2/show/NCT01135056.  http://www.sirvenib.com
  2. Llovet J, Ricci S, Mazzaferro V et al for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008; 359: 378-390.
  3. Cheng A, Kang Y, Chen Z et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.  Lancet Oncology 2009;10: 25-34.
  4. Sangro B, Carpanese L, Cianni R et al on behalf of European Network on Radioembolization with yttrium-90 resin microspheres (ENRY). Survival after [90]Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation. Hepatology 2011; 54: 868-878.
  5. Ferlay J, Soerjomataram I, Ervik M et al. Globocan 2012. v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:http://globocan.iarc.fr , accessed on 6/June/2016.
  6. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. Journal of Hepatology 2012; 56: 908-943.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

329-EUA-0616

Source: Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore, Singapore Clinical Research Institute (SCRI) and Sirtex Medical Limited

Written by asiafreshnews

June 7, 2016 at 2:07 pm

Posted in Uncategorized

Extraordinary Conceptions featured on CCTV to discuss international surrogacy

leave a comment »

— 59% of entrepreneurs globally expect to increase their workforce in 2016, more than double the proportion of large businesses expecting to do so
— Disruptive and innovative entrepreneurs hiring significantly faster than the rest of those surveyed
— Organic growth a clear priority for entrepreneurs this year

LONDON /PRNewswire/ — According to the EY Global Job Creation Survey 2016, entrepreneurs are more than twice as likely to be hiring new staff this year as large corporates. The survey of nearly 2,700 entrepreneurs globally also finds that disruptive entrepreneurs (who change some or all of the rules of their sector) and innovative entrepreneurs (who have created a brand new product or service in the past year) are also growing their workforces at a much faster rate than more conventional entrepreneurs. The research has been launched ahead of the EY World Entrepreneur Of The Year™ event.

Logo – http://photos.prnewswire.com/prnh/20130701/NY40565LOGO-b

Mark Weinberger, EY Global Chairman and CEO, said:

“The disruptive force of technology is transforming individual companies and creating entirely new sectors. In this environment, entrepreneurs are pivotal drivers of global job creation, and in some cases are navigating economic and political uncertainty better than established players.

“Technology is also transforming some of the most fundamental aspects of how we do business. This evolution will change what job skills are needed, which new businesses are created, it will impact our education systems and will challenge our regulatory systems.”

Confidence is driving a global appetite to hire

Over half (59%) of the entrepreneurs from 12 key markets surveyed expect to increase their total global workforce in the next 12 months, up from 47% in 2015, a jump of 25% year-on-year. What’s more, the proportion of entrepreneurs planning to hire this year is more than double that of large corporations (28%), according to EY’s latest Capital Confidence Barometer.

Taking into account all anticipated workforce changes for 2016, entrepreneurs expect to grow their overall global workforce by 9.3%, and expect 12% of new hires to be young people in their first jobs.

India, China and Brazil top the leader board in terms of the proportion of their entrepreneurs anticipating growth. Indian and Brazilian entrepreneurs also expect to hire at a faster rate than anywhere else, but China’s rate of growth is slower than the global average (8.5%). France, Canada, the UK and the US follow closely behind in hiring expectations, with entrepreneurs in the UK leading the developed markets by rate of growth, at 10.5%. Entrepreneurs in the Middle East/North Africa (MENA), Japan and Sub-Saharan Africa (SSA) are least likely to anticipate growing their overall workforce in the year ahead (see Figure 1).

This hiring is driven by strong confidence levels in the economic direction of their domestic market and the global economy – up slightly year-on-year at 72% and 67% respectively overall. However, there are interesting variations by country and region. Confidence is up on both counts year-on-year in the US, the UK, Canada, Brazil, France andAustralia. Confidence is down in China, India, SSA, Germany and Japan.

Disruption and innovation pay dividends for entrepreneurs and employment

The survey also shows that the more disruptive and innovative the company, the more they hire and the faster they do it.

The most disruptive entrepreneurs – the 17% of respondents who say they have changed all or many of the rules in their sector – are 58% more likely to forecast an increase in their overall workforce in 2016 compared to their more conventional competitors. At 18%, the net workforce growth level of these most disruptive entrepreneurs is twice the average global figure. Even when companies changing only “some” of the rules are added to this, the impact of disruption remains clear: they are 46% more likely to grow their workforce compared to more conventional businesses and, at 12%, net workforce growth is still higher than the global average of 9%. This suggests that any level of disruption has a positive impact on anticipated workforce growth.

Globally, there are more disruptive entrepreneurs in MENA (70%), India (64%), Sub-Saharan Africa (60%), Australiaand the UK (both 57%).

Innovative entrepreneurs – those who say they have created an entirely new product or service in the past year – have similar hiring plans. They are 95% more likely to expect to grow their workforce in the next year compared to those who have not created a new product or service. Their net workforce growth levels (at 18%), like their disruptive counterparts, are also twice the global average figure.

Uschi Schreiber, EY Global Vice Chair ‒ Markets, says: “The numbers validate what we have known for some time: the majority of entrepreneurs do well in business by challenging the status quo, asking difficult questions of incumbents and redefining the boundaries of sectors and industries. What is encouraging is that these disruptors are blazing a trail of growth in today’s fast-moving and transformative business environment, spotting opportunities and relentlessly executing on them, very often blind to existing sector or industry boundaries.

“In our view, the findings could be something of a stark warning to businesses that are not embracing innovation, change or disruption, as they risk being left behind by disruptors who, we know from the survey, are laser-focused on attaining the talent that will allow them to attract customers and drive growth. Governments too need to focus on fostering an environment in which innovative and disruptive entrepreneurs can flourish.”

Young entrepreneurs are more disruptive, but older entrepreneurs are more inventive

Youth clearly has a role to play in disruption levels: 65% of entrepreneurs under the age of 35 are “disruptors” compared to just 27% of entrepreneurs over the age of 55. Younger companies are also much more likely to be in the most disruptive category – 59% of entrepreneurial organizations less than five years old identify as disruptive, compared to just 27% that have been in business trading for more than 25 years.

Unlike disruption levels, however, inventiveness and innovation is not linked to youth or tenure of business – in fact, the age group containing the most innovative entrepreneurs is the 65+ segment.

Organic growth will be key to entrepreneurs’ success

Organic growth is seen as key to success with nearly half (46%) of the entrepreneurs reporting growth in the past 12 months saying this was primarily achieved organically.

Rather than focusing on deals, entrepreneurs see generating new business as both their top priority and biggest challenge in the year ahead, with almost half (48%) saying that identifying, attracting and serving new customers is a priority, 27% saying it’s their top priority and 30% saying it’s a challenge for growth. Developing new products and services (34%) and attracting bright new talent (32%) were the next most cited growth priorities. Only 15% see M&A or alliances as a growth priority at all this year, and only 3% see it as their top priority. This is in direct contrast to larger corporates, where half are planning an M&A transaction in the next year and 40% are considering alliances, according to EY’s Capital Confidence Barometer.

Schreiber says: “Entrepreneurs play a key role in helping realize the benefits of disruption through the jobs and wealth they create, the new products and services they produce and in the way they encourage creativity and competition.

“We know from our work with entrepreneurs around the world that they have the best chance of success when they operate inside a healthy entrepreneurial ecosystem. Whether they are targeting organic or inorganic growth, entrepreneurs need an environment where governments, large businesses and entrepreneurs can work closely together to create the right conditions for entrepreneurship to thrive.”

Figure 1: Hiring plans by territory

Territory

% expect to increase
overall workforce

Net anticipated workforce growth %
(includes growth/static/decline)

Global total

59

+9.3

India

76

+14.5

China

68

+8.5

Brazil

67

+19

France

66

+10

Canada

64

+7

UK

63

+10.5

US

63

+10

Australia

61

+9

Germany

53

+3

MENA

41

+5

Japan

28

+3

Sub-Saharan Africa

7

+1

For the full report please click here.

Notes to Editors

About EY

EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

This news release has been issued by EYGM Limited, a member of the global EY organization that also does not provide any services to clients.

The EY Global Job Creation Survey2016

The EY Global Job Creation Survey2016 was conducted online between January and March 2016 with an independent panel of global entrepreneurs in 12 key global markets, including input from 245 of the world’s most dynamic entrepreneurs – EY Entrepreneur Of The Year™ participants. The results are based on the responses of 2,673 entrepreneurs in Germany, China, India, France, Brazil, Japan, Australia, Canada, the UK, the US, Sub-Saharan Africa and MENA. Opinion Matters, part of the markettiers4dc group of companies in the UK and overseas, conducted the research for EY. The research adheres to strict industry codes of conduct and ICC/ESOMAR global market research guidelines.

Source: EY
Related Links:

Written by asiafreshnews

June 7, 2016 at 12:03 pm

Posted in Uncategorized

Entrepreneurs’ hiring plans increase as their confidence in the global economy holds steady

leave a comment »

— 59% of entrepreneurs globally expect to increase their workforce in 2016, more than double the proportion of large businesses expecting to do so
— Disruptive and innovative entrepreneurs hiring significantly faster than the rest of those surveyed
— Organic growth a clear priority for entrepreneurs this year

LONDON /PRNewswire/ — According to the EY Global Job Creation Survey 2016, entrepreneurs are more than twice as likely to be hiring new staff this year as large corporates. The survey of nearly 2,700 entrepreneurs globally also finds that disruptive entrepreneurs (who change some or all of the rules of their sector) and innovative entrepreneurs (who have created a brand new product or service in the past year) are also growing their workforces at a much faster rate than more conventional entrepreneurs. The research has been launched ahead of the EY World Entrepreneur Of The Year™ event.

Logo – http://photos.prnewswire.com/prnh/20130701/NY40565LOGO-b

Mark Weinberger, EY Global Chairman and CEO, said:

“The disruptive force of technology is transforming individual companies and creating entirely new sectors. In this environment, entrepreneurs are pivotal drivers of global job creation, and in some cases are navigating economic and political uncertainty better than established players.

“Technology is also transforming some of the most fundamental aspects of how we do business. This evolution will change what job skills are needed, which new businesses are created, it will impact our education systems and will challenge our regulatory systems.”

Confidence is driving a global appetite to hire

Over half (59%) of the entrepreneurs from 12 key markets surveyed expect to increase their total global workforce in the next 12 months, up from 47% in 2015, a jump of 25% year-on-year. What’s more, the proportion of entrepreneurs planning to hire this year is more than double that of large corporations (28%), according to EY’s latest Capital Confidence Barometer.

Taking into account all anticipated workforce changes for 2016, entrepreneurs expect to grow their overall global workforce by 9.3%, and expect 12% of new hires to be young people in their first jobs.

India, China and Brazil top the leader board in terms of the proportion of their entrepreneurs anticipating growth. Indian and Brazilian entrepreneurs also expect to hire at a faster rate than anywhere else, but China’s rate of growth is slower than the global average (8.5%). France, Canada, the UK and the US follow closely behind in hiring expectations, with entrepreneurs in the UK leading the developed markets by rate of growth, at 10.5%. Entrepreneurs in the Middle East/North Africa (MENA), Japan and Sub-Saharan Africa (SSA) are least likely to anticipate growing their overall workforce in the year ahead (see Figure 1).

This hiring is driven by strong confidence levels in the economic direction of their domestic market and the global economy – up slightly year-on-year at 72% and 67% respectively overall. However, there are interesting variations by country and region. Confidence is up on both counts year-on-year in the US, the UK, Canada, Brazil, France andAustralia. Confidence is down in China, India, SSA, Germany and Japan.

Disruption and innovation pay dividends for entrepreneurs and employment

The survey also shows that the more disruptive and innovative the company, the more they hire and the faster they do it.

The most disruptive entrepreneurs – the 17% of respondents who say they have changed all or many of the rules in their sector – are 58% more likely to forecast an increase in their overall workforce in 2016 compared to their more conventional competitors. At 18%, the net workforce growth level of these most disruptive entrepreneurs is twice the average global figure. Even when companies changing only “some” of the rules are added to this, the impact of disruption remains clear: they are 46% more likely to grow their workforce compared to more conventional businesses and, at 12%, net workforce growth is still higher than the global average of 9%. This suggests that any level of disruption has a positive impact on anticipated workforce growth.

Globally, there are more disruptive entrepreneurs in MENA (70%), India (64%), Sub-Saharan Africa (60%), Australiaand the UK (both 57%).

Innovative entrepreneurs – those who say they have created an entirely new product or service in the past year – have similar hiring plans. They are 95% more likely to expect to grow their workforce in the next year compared to those who have not created a new product or service. Their net workforce growth levels (at 18%), like their disruptive counterparts, are also twice the global average figure.

Uschi Schreiber, EY Global Vice Chair ‒ Markets, says: “The numbers validate what we have known for some time: the majority of entrepreneurs do well in business by challenging the status quo, asking difficult questions of incumbents and redefining the boundaries of sectors and industries. What is encouraging is that these disruptors are blazing a trail of growth in today’s fast-moving and transformative business environment, spotting opportunities and relentlessly executing on them, very often blind to existing sector or industry boundaries.

“In our view, the findings could be something of a stark warning to businesses that are not embracing innovation, change or disruption, as they risk being left behind by disruptors who, we know from the survey, are laser-focused on attaining the talent that will allow them to attract customers and drive growth. Governments too need to focus on fostering an environment in which innovative and disruptive entrepreneurs can flourish.”

Young entrepreneurs are more disruptive, but older entrepreneurs are more inventive

Youth clearly has a role to play in disruption levels: 65% of entrepreneurs under the age of 35 are “disruptors” compared to just 27% of entrepreneurs over the age of 55. Younger companies are also much more likely to be in the most disruptive category – 59% of entrepreneurial organizations less than five years old identify as disruptive, compared to just 27% that have been in business trading for more than 25 years.

Unlike disruption levels, however, inventiveness and innovation is not linked to youth or tenure of business – in fact, the age group containing the most innovative entrepreneurs is the 65+ segment.

Organic growth will be key to entrepreneurs’ success

Organic growth is seen as key to success with nearly half (46%) of the entrepreneurs reporting growth in the past 12 months saying this was primarily achieved organically.

Rather than focusing on deals, entrepreneurs see generating new business as both their top priority and biggest challenge in the year ahead, with almost half (48%) saying that identifying, attracting and serving new customers is a priority, 27% saying it’s their top priority and 30% saying it’s a challenge for growth. Developing new products and services (34%) and attracting bright new talent (32%) were the next most cited growth priorities. Only 15% see M&A or alliances as a growth priority at all this year, and only 3% see it as their top priority. This is in direct contrast to larger corporates, where half are planning an M&A transaction in the next year and 40% are considering alliances, according to EY’s Capital Confidence Barometer.

Schreiber says: “Entrepreneurs play a key role in helping realize the benefits of disruption through the jobs and wealth they create, the new products and services they produce and in the way they encourage creativity and competition.

“We know from our work with entrepreneurs around the world that they have the best chance of success when they operate inside a healthy entrepreneurial ecosystem. Whether they are targeting organic or inorganic growth, entrepreneurs need an environment where governments, large businesses and entrepreneurs can work closely together to create the right conditions for entrepreneurship to thrive.”

Figure 1: Hiring plans by territory

Territory

% expect to increase
overall workforce

Net anticipated workforce growth %
(includes growth/static/decline)

Global total

59

+9.3

India

76

+14.5

China

68

+8.5

Brazil

67

+19

France

66

+10

Canada

64

+7

UK

63

+10.5

US

63

+10

Australia

61

+9

Germany

53

+3

MENA

41

+5

Japan

28

+3

Sub-Saharan Africa

7

+1

For the full report please click here.

Notes to Editors

About EY

EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

This news release has been issued by EYGM Limited, a member of the global EY organization that also does not provide any services to clients.

The EY Global Job Creation Survey2016

The EY Global Job Creation Survey2016 was conducted online between January and March 2016 with an independent panel of global entrepreneurs in 12 key global markets, including input from 245 of the world’s most dynamic entrepreneurs – EY Entrepreneur Of The Year™ participants. The results are based on the responses of 2,673 entrepreneurs in Germany, China, India, France, Brazil, Japan, Australia, Canada, the UK, the US, Sub-Saharan Africa and MENA. Opinion Matters, part of the markettiers4dc group of companies in the UK and overseas, conducted the research for EY. The research adheres to strict industry codes of conduct and ICC/ESOMAR global market research guidelines.

Source: EY
Related Links:

Written by asiafreshnews

June 7, 2016 at 11:48 am

Posted in Uncategorized